Growth Hormone
Extended GH Release Studies
Quantity
Ships from the United States with tracking · free shipping over $200
Certificates of analysis
Each certificate covers one production run, and reports on that batch alone. Open any of them to read the laboratory report exactly as the third-party lab issued it.
Authenticity
Scan the code on the label to pull up every published certificate for that compound — the same reports the third-party laboratory issued, batch by batch. Traceable from the laboratory that tested it to your bench.
Verify a batch →Independently tested
Purity is quantified by reverse-phase HPLC and identity confirmed by mass spectrometry, by an outside laboratory rather than in-house.
A certificate for your lot
The report that ships with your order describes the batch you received — not the product line, and not a representative sample.
COA-backed replacement
If material does not match the certificate issued for its lot, we replace it or refund it. Send us the lot number and we will trace it.
Tracked dispatch
Tracking is issued when the label is created, so the shipment is traceable from the moment it leaves us.
About this compound
C152H252N44O42
The DAC variant adds a drug affinity complex — a chemical linker that binds circulating albumin. Because albumin turns over slowly, the linker extends the compound's half-life from minutes into days. That single structural difference is what separates it from standard CJC-1295, and it is the property most research on the compound is built around.
Full specification
How it works
The pathways CJC-1295 DAC acts on, and what each one does. Signalling described from preclinical models.
GHRH Receptor Activation
A 30-residue GHRH(1–29) analogue carrying four substitutions that block protease cleavage. The receptor interaction matches native GHRH; the substitutions only determine how long the molecule survives to use it.
Albumin Binding — Half-Life Extension
The drug affinity complex is a maleimidopropionic acid group at Lys8 that binds circulating albumin after injection. Because albumin turns over slowly, half-life extends from minutes into days — this is the entire difference from the non-DAC version.
Downstream IGF-1 Elevation
Sustained rather than pulsatile growth hormone exposure drives continuous hepatic IGF-1 production. Whether that steady profile is preferable to a pulsatile one is the open question separating the two variants.
Uses & applications
The main areas under study, and the study-reported figures behind them.
The albumin linker turns a minutes-long half-life into days, so exposure is continuous rather than pulsed. That is the variable this compound exists to test.
Teichman et al. 2006
Binding circulating albumin creates a slow-release depot. Because albumin turns over slowly, the peptide is released gradually rather than cleared.
Teichman et al. 2006
Activity stays at the GHRH receptor rather than spilling into the ghrelin pathway, which keeps the pituitary's own feedback intact.
Teichman et al. 2006
Animal models measure whether sustained upstream stimulation restores growth trajectories, using the non-DAC variant as the comparison.
Alba et al. 2006
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Molecular structure
The verified reference values for this compound.
No 3D structure published
This compound is a long, flexible chain. Any single three-dimensional arrangement would be one of an enormous number it can adopt, so we do not show one. The sequence and the reference values beside this are the reliable description.
C152H252N44O42
Third-party verified
Every batch of CJC-1295 DAC is sent to an accredited independent laboratory before it ships. Here is what we screen for.
Quantifies purity and reports it on the lot certificate
Verifies the exact molecular identity
Lead, arsenic, cadmium & mercury
Bacterial endotoxin levels
No microbial contamination
Actual peptide mass per vial verified
FAQ
The DAC variant adds a drug affinity complex — a chemical linker that binds circulating albumin. Because albumin turns over slowly, the linker extends the compound's half-life from minutes into days. That single structural difference is what separates it from standard CJC-1295, and it is the property most research on the compound is built around.
Published research on CJC-1295 DAC concentrates on Sustained GH Stimulation, Albumin-Depot Mechanism, GHRH Axis Selectivity and Growth Normalization. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes CJC-1295 DAC acting across GHRH Receptor Activation, Albumin Binding — Half-Life Extension and Downstream IGF-1 Elevation, reported respectively as GHRH-R Agonist, DAC Technology and IGF-1 Axis. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
CJC-1295 DAC has a molecular formula of C152H252N44O42 and an average mass of 3367.97 g/mol. It is indexed under CAS 863288-34-0. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. CJC-1295 DAC is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. CJC-1295 DAC is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed and peer-reviewed journals — not Routine Peptides claims.
For research use only
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
